Anavex strengthens scientific advisory board with investigator from phase 2b/3 alzheimer's trial

New york, dec. 14, 2022 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) diseases, today announced the appointment of prof. dr. timo grimmer, md, to its scientific advisory board. prof. dr. grimmer served as national coordinating investigator for the anavex®2-73 (blarcamesine) phase 2b/3 anavex®2-73-ad-004 study.
AVXL Ratings Summary
AVXL Quant Ranking